Presentation is loading. Please wait.

Presentation is loading. Please wait.

A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing–Based Circulating Tumor DNA Profiling Exhibits Excellent Response.

Published byἜρεβος Μιχαλολιάκος Modified over 6 years ago

Similar presentations

Presentation on theme: "A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing–Based Circulating Tumor DNA Profiling Exhibits Excellent Response."— Presentation transcript:

1 A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing–Based Circulating Tumor DNA Profiling Exhibits Excellent Response to Crizotinib  Yan Yang, MD, PhD, Shu-Kui Qin, MD, PhD, Jian Zhu, MD, Rui Wang, MD, Yu-Mei Li, MD, Zong-Yu Xie, MD, Qiong Wu, MD, PhD  Mayo Clinic Proceedings: Innovations, Quality & Outcomes   Volume 1, Issue 1, Pages (July 2017) DOI: /j.mayocpiqo Copyright © 2017 Mayo Foundation for Medical Education and Research Terms and Conditions

2 Figure 1 Imaging characteristics of the patient during chemotherapy. A, Chest CT scan after first-line chemotherapy showed enlarged paratracheal lymph nodes in the mediastinum and a nodule on the right pleura. B, Chest CT scan after 6 cycles of second-line chemotherapy showed tumor progression. CT = computed tomography. Mayo Clinic Proceedings: Innovations, Quality & Outcomes  2017 1, DOI: ( /j.mayocpiqo ) Copyright © 2017 Mayo Foundation for Medical Education and Research Terms and Conditions

3 Figure 2 Identification of STRN-ALK fusion in the patient’s paraffin-embedded surgical samples. A, Paired-end sequencing data from tumor tissue samples indicated somatic intrachromosomal STRN-ALK fusion as demonstrated by Integrative Genomics Viewer program. B, Confirmation of the STRN-ALK fusion by polymerase chain reaction. The expected product size is 166 bp. C, DNA sequence chromatograms show the conjoined regions at the DNA sequence level of the STRN-ALK fusion gene. D, Schematic diagram of the predicted domains of the STRN-ALK fusion protein. M = marker (100-bp ladder); NC = negative control; P = paraffin-embedded tissue sample. Mayo Clinic Proceedings: Innovations, Quality & Outcomes  2017 1, DOI: ( /j.mayocpiqo ) Copyright © 2017 Mayo Foundation for Medical Education and Research Terms and Conditions

4 Figure 3 Imaging characteristics of the patient during crizotinib treatment. Chest CT-enhanced scans were shown before (A) and 1 month (B), 2 months (C), and 6 months (D) after initiation of crizotinib therapy, demonstrating dramatic shrinkage of tumor lesions. E, Lumbar MRI after first-line therapy revealed an apparent enhancement of lesion at the L5 vertebral body after intensification, indicating the existence of bone metastases. F, Lumbar MRI after treatment with crizotinib for 2 months showed limited scope for reinforcement. MRI = magnetic resonance imaging. Mayo Clinic Proceedings: Innovations, Quality & Outcomes  2017 1, DOI: ( /j.mayocpiqo ) Copyright © 2017 Mayo Foundation for Medical Education and Research Terms and Conditions

5 Figure 4 Noninvasive detection and monitoring of ctDNA using targeted NGS. Dynamic changes in tumor burden (A) and carcinoembryonic antigen (B) in response to crizotinib treatment were closely correlated with alterations in fractional abundance of STRN-ALK in plasma. C, Concordance between different reporters (SNVs and fusion) in response to crizotinib. APC = adenomatous polyposis coli; CEA = carcinoembryonic antigen; ctDNA = circulating tumor DNA; MAF = mutant allele frequency; MAP2K1 = mitogen-activated protein kinase kinase 1; NGS = next-generation sequencing; SNV = single nucleotide variant; STAT3 = signal transducer and activator of transcription 3; TP53 = tumor protein 53. Mayo Clinic Proceedings: Innovations, Quality & Outcomes  2017 1, DOI: ( /j.mayocpiqo ) Copyright © 2017 Mayo Foundation for Medical Education and Research Terms and Conditions

Download ppt "A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing–Based Circulating Tumor DNA Profiling Exhibits Excellent Response."

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.
A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing–Based Circulating Tumor DNA Profiling Exhibits Excellent Response.

A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing–Based Circulating Tumor DNA Profiling Exhibits Excellent Response.
Christopher J. Klein, MD, Tatiana M. Foroud, PhD 

Christopher J. Klein, MD, Tatiana M. Foroud, PhD 
Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib  C. Leitner, R. von Moos,

Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib  C. Leitner, R. von Moos,
Droplet Digital PCR for Absolute Quantification of EML4-ALK Gene Rearrangement in Lung Adenocarcinoma  Qiushi Wang, Xin Yang, Yong He, Qiang Ma, Li Lin,

Droplet Digital PCR for Absolute Quantification of EML4-ALK Gene Rearrangement in Lung Adenocarcinoma  Qiushi Wang, Xin Yang, Yong He, Qiang Ma, Li Lin,
Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced.

Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced.
Cidofovir Treatment of Progressive Multifocal Leukoencephalopathy in a Patient Receiving Highly Active Antiretroviral Therapy  Raymund R. Razonable, MD,

Cidofovir Treatment of Progressive Multifocal Leukoencephalopathy in a Patient Receiving Highly Active Antiretroviral Therapy  Raymund R. Razonable, MD,
Christopher J. Klein, MD, Tatiana M. Foroud, PhD 

Christopher J. Klein, MD, Tatiana M. Foroud, PhD 
PET/CT Fusion Scan in Lung Cancer: Current Recommendations and Innovations  Cristina Gámez, MD, PhD, Rafael Rosell, MD, PhD, Alejandro Fernández, MD, PhD,

PET/CT Fusion Scan in Lung Cancer: Current Recommendations and Innovations  Cristina Gámez, MD, PhD, Rafael Rosell, MD, PhD, Alejandro Fernández, MD, PhD,
Diagnostic Approach to the Complexity of IgG4-Related Disease

Diagnostic Approach to the Complexity of IgG4-Related Disease
WT1 Promotes Invasion of NSCLC via Suppression of CDH1

WT1 Promotes Invasion of NSCLC via Suppression of CDH1
Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse  Karinna.

Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse  Karinna.
Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment  Jun Soo Ham, MD, Seokhwi Kim, MD, Hee Kyung.

Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment  Jun Soo Ham, MD, Seokhwi Kim, MD, Hee Kyung.
Rima Abu-Nader, MD, Christine L. Terrell, MD  Mayo Clinic Proceedings 

Rima Abu-Nader, MD, Christine L. Terrell, MD  Mayo Clinic Proceedings 
T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis  Hugo Gortais,

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis  Hugo Gortais,
Hiren J. Mehta, MD, Tan-Lucien Mohammed, MD, Michael A. Jantz, MD 

Hiren J. Mehta, MD, Tan-Lucien Mohammed, MD, Michael A. Jantz, MD 
Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC  Kai Chen, MD, Fei Zhou, MD, Wenxiang Shen,

Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC  Kai Chen, MD, Fei Zhou, MD, Wenxiang Shen,
Recent Advances in Targeting ROS1 in Lung Cancer

Recent Advances in Targeting ROS1 in Lung Cancer
Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance.

Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance.
Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic.

Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic.

Similar presentations

Ads by Google